Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 26, 2025

3 Leading AI Stocks Investors Can Buy for 2026 (NVDA, AVGO, VRT)

View original at finance.yahoo.com
3 Leading AI Stocks Investors Can Buy for 2026 (NVDA, AVGO, VRT) The market, and many leading AI stocks, are at an inflection point. In the near term, further volatility or even a pullback is possible…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Nvidia acquisition was described as a 'non-exclusive licensing agreement'

    80% confidence

  • Management highlighted strong backlog growth and improving visibility tied directly to AI-driven capacity expansion

    80% confidence

  • Nvidia, Broadcom, and Vertiv are among the most critical enablers of the AI expansion

    80% confidence

  • As Alphabet's AI leadership has become clearer, Broadcom's strategic importance has risen alongside it

    80% confidence

  • The acquisition strengthens Nvidia's already formidable moat at the leading edge of AI semiconductors

    80% confidence

  • Broadcom plays a critical role in Google's TPU ecosystem by providing underlying expertise in ASIC design, networking, and high-speed I/O

    80% confidence

  • AI capital spending is projected to reach an estimated $571 billion in 2026

    80% confidence

  • The current setup favors accumulation opportunistically as the AI investment cycle extends into 2026 and beyond

    80% confidence

  • Demand for high-density cooling solutions continues to exceed expectations as next-generation AI workloads push power and thermal limits higher

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
3 Leading AI Stocks Investors Can Buy for 2026 (NVDA, AVGO, VRT) — Source | Via News | ViaNews EU